BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Dry eye and glaucoma clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for glaucoma: 78 (53 sponsors; 15 newly posted in the last 180 days, 2 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 10.3, rank 64 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 4, Phase 2 11, Phase 3 10, Phase 4 4, N/A 49.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
SpyGlass Pharma, Inc. SGP5P1 1, NA 1, P3 2, P2 111
Glaukos Corporation GKOS7P4 2, P2 1, NA 3, P3 112
AbbVie ABBV3P4 1, P2 1, P3 100
Ache Laboratorios Farmaceuticos S.A. new entrant1P3 110
Amneal Pharmaceuticals, LLC AMRX1P3 100
Huons Co., Ltd.1P3 100
Omikron Italia S.r.l.1P3 100
Santen Pharmaceutical Co., Ltd.1P3 100
YS Life Science Co., Ltd. new entrant1P3 110
iSTAR Medical6NA 602
Iantrek, Inc.4NA 402
Laboratoires Thea2P2 1, NA 100
Nova Eye, Inc. NVMI2NA 201
PolyActiva Pty Ltd2P1 1, P2 101
Sight Sciences, Inc. SGHT2NA 201
VividWhite Pty Ltd2NA 210
Alcon Research ALC1NA 100
Aquea Health, Inc. new entrant1NA 110
Astellas Pharma Global Development, Inc. new entrant1P2 110
Avisi Technologies Inc.1NA 100
Bayer1NA 100
BelkinVision1NA 100
Centervue SpA1NA 100
Ciliatech1NA 100
Clinical Research Consultants, Inc. new entrant1NA 110

New-entrant sponsors: Ache Laboratorios Farmaceuticos S.A., YS Life Science Co., Ltd., Aquea Health, Inc., Astellas Pharma Global Development, Inc., Clinical Research Consultants, Inc..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2/P3Oculis OCSNCT07548632 A Clinical Study Evaluating Licaminlimab for Dry Eye DiseaseDry Eye Disease (DED)active not recruiting160
2026-12-27 est.P2Dompé Farmaceutici S.p.ANCT07503886 An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseaseDry Eye Disease (DED)recruiting417
2027-01 est.P1/P2EyeD PharmaNCT07036510 Safety and Efficacy of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract SurgeryGlaucoma; Ocular Hypertensionrecruiting42
2027-01-21 est.P2Laboratoires TheaNCT07169695 A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal KeratoconjunctivitisModerate to Severe Vernal Keratoconjunctivitisrecruiting120
2027-02 est.P2Bausch & Lomb Incorporated BLCONCT07778888 BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution TrialDry Eye Diseaserecruiting20

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-15 est.P2PolyActiva Pty LtdNCT06964191 Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma, Open-Angle; Ocular Hypertensionactive not recruiting75
2026-11 est.P2BRIM Biotechnology Inc.NCT07078955 A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye DiseaseDry Eye Disease (DED); Keratoconjunctivitis Siccanot yet recruiting99
2026-10-01P2Qlaris Bio, Inc.NCT07354477 Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel DilationNon-proliferative Diabetic Retinopathy (NPDR); Open-angle Glaucoma (OAG); Normal Tension Glaucoma (Ncompleted9
2026-10 est.P2Taejoon Pharmaceutical Co., Ltd.NCT07810972 Evaluate the Safety and Efficacy of TJO-087Dry Eye Syndrome (DES)active not recruiting90
2026-09 est.P2Vanda Pharmaceuticals VNDANCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry EyeDry Eyerecruiting160
2026-08-31 est.P3Santen Pharmaceutical Co., Ltd.NCT06666855 A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in ChinaOpen Angle Glaucoma; Ocular Hypertensionactive not recruiting345
2026-08-21P3AbbVie ABBVNCT07284381 A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult ParticipanDry Eye Diseasecompleted261
2026-07-22P2/P3Qlaris Bio, Inc.NCT07354516 Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular HypertensionOAG - Open-Angle Glaucoma; OHT - Ocular Hypertensioncompleted64
2026-06-19P3AbbVie ABBVNCT03891446 Long-term Safety and Efficacy Extension Trial of Bimatoprost SROpen-Angle Glaucoma; Ocular Hypertensioncompleted455
2026-05-28P2Bausch & Lomb Incorporated BLCONCT07128628 A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye DiseaseDry Eye Diseasecompleted443

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "glaucoma"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.